Invasive aspergillosis in children with hematological malignancies

References

• Rankin N. Disseminated aspergillosis and moniliasis associated with agranulocytosis and antibiotic therapy. Br. Med. J.1, 918–919 (1953).
   PubMedGoogle Scholar
• McNeil MM, Nash SL, Hejjeh RA et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980 to 1997. Clin. Infect. Dis.33, 641–647 (2001).
   PubMed Web of Science ®Google Scholar
• Krishnan S, Manavathu EK, Chandrasekar PH. Aspergillus flavus: an emerging non-fumigatus Aspergillus species of significance. Mycoses52, 206–222 (2009).
   PubMed Web of Science ®Google Scholar
• Özen M. Invasive infections caused by molds. J. Pediatr. Inf.3(Suppl. 1), 105–107 (2009).
   Google Scholar
• Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis.34, 909–917 (2002).
   PubMed Web of Science ®Google Scholar
• McNeil MM, Nash SL, Hajjeh RA et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980–1997. Clin. Infect. Dis.33, 641–647 (2001).
   PubMed Web of Science ®Google Scholar
• Crassard N, Hadden H, Piens MA et al. Invasive aspergillosis in a paediatric haematology department: a 15-year review. Mycoses51, 109–116 (2008).
   PubMed Web of Science ®Google Scholar
• Rubio PM, Sevilla J, González-Vicent M et al. Increasing incidence of invasive aspergillosis in pediatric hematology oncology patients over the last decade: a retrospective single centre study. J. Pediatr. Hematol. Oncol.31, 642–646 (2009).
   PubMed Web of Science ®Google Scholar
• Lass-Florl C. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses52, 197–205 (2009).
   PubMed Web of Science ®Google Scholar
• Camps IR. Risk factors for invasive fungal infections in haematopoietic stem cell transplantation. Int. J. Antimicrob. Agents.32(Suppl. 2), S119–S123 (2008).
   PubMed Web of Science ®Google Scholar
• Mikulska M, Raiola AM, Bruno B et al. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients. Bone Marrow Transplant.44, 361–370 (2009).
   PubMed Web of Science ®Google Scholar
• Nucci M, Anaissie E. Fungal infections in hematopoietic stem cell transplantation and solid-organ transplantation – focus on aspergillosis. Clin. Chest Med.30, 295–306 (2009).
   PubMed Web of Science ®Google Scholar
• Segal BH. Aspergillosis. N. Engl. J. Med.360, 1870–1884 (2009).
   PubMed Web of Science ®Google Scholar
• Ben-Amis R, Lewis RE, Kontoyiannis DP. Invasive mould infections in the setting of hematopoietic cell transplantation: current trends and new challenges. Curr. Opin. Infect. Dis.22, 376–384 (2009).
   PubMedGoogle Scholar
• Gallin JI, Zarember K. Lessons about the pathogenesis and management of aspergillosis from studies in chronic granulomatous disease. Trans. Am. Clin. Climatol. Assoc.118, 175–185 (2007).
   PubMedGoogle Scholar
• Burgos A, Zaoutis TE, Dvorak CC et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics121, e1286–e1294 (2008).
   PubMed Web of Science ®Google Scholar
• Blum MD, Wiedermann BL. Aspergillus infections. In: Textbook of Pediatric Infectious Diseases (5th Edition). Feigin RD, Cherry JD, Demmler GJ, Kaplan SL (Eds). Saunders, PA, USA, 2550–2560 (2004).
   Google Scholar
• Thomas L, Baggen L, Chisholm J, Sharland M. Diagnosis and treatment of aspergillosis in children. Expert Rev. Anti Infect. Ther.7, 461–472 (2009).
   PubMed Web of Science ®Google Scholar
• Panda NK, Balaji P, Chakrabarti A, Sharma SC, Reddy CEE. Paranasal sinus aspergillosis: its categorization to develop a treatment protocol. Mycoses47, 277–283 (2004).
   PubMed Web of Science ®Google Scholar
• Dotis J, Iosifidis E, Roilides E. Central nervous system aspergillosis in children: a systematic review of reported cases. Int. J. Infect. Dis11, 381–393 (2007).
   PubMed Web of Science ®Google Scholar
• Van Burik JH, Colven R, Spach DH. Cutaneous aspergillosis. J. Clin. Microbiol.36, 3115–3121 (1998).
   PubMedGoogle Scholar
• Bochennek K, Abolmaali N, Wittekindt B et al. Diagnostic approaches for immunocompromised paediatric patients with pulmonary infiltrates. Clin. Microbiol. Infect.12, 199–201 (2006).
   PubMed Web of Science ®Google Scholar
• Abramson S. The air crescent sign. Radiology218, 230–232 (2001).
   PubMed Web of Science ®Google Scholar
• Thomas KE, Owens CM, Veys PA, Novelli V, Costoli V. The radiological spectrum of invasive aspergillosis in children: a 10-year review. Pediatr. Radiol.33, 453–460 (2003).
   PubMed Web of Science ®Google Scholar
• Steinbach WJ. Invasive aspergillosis in pediatric patients. Curr. Med. Res. Opin26, 1779–1787 (2010).
   PubMed Web of Science ®Google Scholar
• Leeflang MM, Debets-Ossenkopp YJ, Visser CE et al. Galactomannan detection for invasive aspergillosis 2 in immunocompromized patients. Cochrane Database Syst. Rev. (4), CD007394 (2008).
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Addison RM, McLaughlin L et al. Prospective Aspergillus galactomannan antigen testing in pediatric hematopoietic stem cell transplant recipients. Pediatr. Infect. Dis. J.26, 558–564 (2007).
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Letscher-Bru V, Oprea C et al.Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J. Clin. Oncol.20, 1898–1906 (2002).
   PubMed Web of Science ®Google Scholar
• Verdaguer V, Walsh TJ, Hope W, Cortez KJ. Galactomannan antigen detection in the diagnosis of invasive aspergillosis. Expert Rev. Mol. Diagn.7, 21–32 (2007).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis.46, 327–360 (2008).
   PubMed Web of Science ®Google Scholar
• Khot PD, Ko DL, Hackman RC, Fredricks DN. Development and optimization of quantitative PCR for the diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. BMC Infect. Dis8, 73 (2008).
   PubMed Web of Science ®Google Scholar
• Roilides E. Early diagnosis of invasive aspergillosis in infants and children. Med. Mycol.44(Suppl. 1), 199–205 (2006).
   PubMed Web of Science ®Google Scholar
• Hummel M, Spiess B, Roder J et al. Detection of Aspergillus DNA by a nested PCR assay is able to improve the diagnosis of invasive aspergillosis in paediatric patients. J. Med. Microb.58, 1291–1297 (2009).
   PubMed Web of Science ®Google Scholar
• Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO); Böhme A, Ruhnke M, Buchheidt D et al. Treatment of invasive fungal infections in cancer patients – recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann. Hematol.88, 97–110 (2009).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Lutsar I, Driscoll T et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr. Infect. Dis. J.21, 240–248 (2002).
   PubMed Web of Science ®Google Scholar
• Lass-Flörl C. Invasive fungal infections in pediatric patients: a review focusing on antifungal therapy. Expert Rev. Anti Infect. Ther8, 127–135 (2010).
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis34, 909–917 (2002).
   PubMed Web of Science ®Google Scholar
• Martino R, Subirá M, Rovira M et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br. J. Haematol.116, 475–482 (2002).
   PubMed Web of Science ®Google Scholar
• Maschmeyer G, Haas A, Cornely OA. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs67, 1567–1601 (2007).
   PubMed Web of Science ®Google Scholar
• Wiley JM, Seibel NL, Walsh TJ. Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections. Pediatr. Infect. Dis. J.24, 167–174 (2005).
   PubMed Web of Science ®Google Scholar
• Kolve H, Ahlke E, Fegeler W, Ritter J, Jürgens H, Groll AH. Safety, tolerance and outcome of treatment with liposomal amphotericin B in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation. J. Antimicrob. Chemother.64, 383–387 (2009).
   PubMed Web of Science ®Google Scholar
• Prasad PA, Coffin SE, Leckerman KH, Walsh TJ, Zaoutis TE. Pediatric antifungal utilization: new drugs, new trends. Pediatr. Infect. Dis. J.27, 1083–1088 (2008).
   PubMed Web of Science ®Google Scholar
• Cesaro S, Giacchino M, Locatelli F et al. Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients. BMC Infect. Dis.7, 28 (2007).
   PubMed Web of Science ®Google Scholar
• Zaoutis TE, Jafri HS, Huang LM et al. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics123, 877–884 (2009).
   PubMed Web of Science ®Google Scholar
• VandenBussche HL, Van Loo DA. A clinical review of echinocandins in pediatric patients. Ann. Pharmacother.44(1), 166–177 (2010).
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Groll AH. Micafungin: a brief review of pharmacology, safety, and antifungal efficacy in pediatric patients. Pediatr. Blood Cancer55(2), 229–232 (2010).
   PubMed Web of Science ®Google Scholar
• Ayper S. Treatment of invasive fungal infections. J. Pediatr Inf3(Suppl. 1), 112–115 (2009).
   Google Scholar
• Steinbach WJ, Stevens DA. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin. Infect. Dis.37(Suppl. 3), 157–187 (2003).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Viviani MA, Arathoon E et al. New targets and delivery systems for antifungal therapy. Med. Mycol.38, 335–347 (2000).
   PubMed Web of Science ®Google Scholar
• Smith WJ, Drew RH, Perfect JR. Posaconazole’s impact on prophylaxis and treatment of invasive fungal infections: an update. Expert Rev. Anti Infect. Ther.7(2), 165–181 (2009).
   PubMed Web of Science ®Google Scholar
• Ayberkin E, Çiftçi E. Aspergillus infections in children. J. Pediatr. Inf.3, 118–125 (2009).
   Google Scholar
• Schwartz S, Ruhnke M, Ribaud P et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood106, 2641–2645 (2005).
   PubMed Web of Science ®Google Scholar
• Khoury H, Adkins D, Miller G et al. Resolution of invasive central nervous system aspergillosis in a transplant recipient. Bone Marrow Transplant.20, 179–180 (1997).
   PubMedGoogle Scholar
• Coleman J, Hogg G, Rosenfeld J, Waters K. Invasive central nervous system aspergillosis: cure with liposomal amphotericin B, itraconazole, and radical surgery – case report and review of the literature. Neurosurgery36, 858–863 (1995).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Raad I, Patterson TF et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis.44, 2–12 (2007).
   PubMed Web of Science ®Google Scholar
• Pitisuttithum P, Negroni R, Graybill JR et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J. Antimicrob. Chemother.56, 745–755 (2005).
   PubMed Web of Science ®Google Scholar
• Maertens J, Raad I, Petrikkos G et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis.39, 1563–1571 (2004).
   PubMed Web of Science ®Google Scholar
• Clemons KV, Espiritu M, Parmar R, Stevens DA. Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob. Agents Chemother.49, 4867–4875 (2005).
   PubMed Web of Science ®Google Scholar
• Weber RS, Lopez-Berestein G. Treatment of invasive Aspergillus sinusitis with liposomal-amphotericin B. Laryngoscope97, 937–941 (1987).
   PubMed Web of Science ®Google Scholar
• Denning DW, Griffiths CE. Muco-cutaneous retinoid-effects and facialerythema related to the novel triazole antifungal agent voriconazole. Clin. Exp. Dermatol.26, 648–653 (2001).
   PubMed Web of Science ®Google Scholar
• Said T, Nampoory MR, Nair MP et al. Safety of caspofungin for treating invasive nasal sinus aspergillosis in a kidney transplant recipient. Transplant Proc.37, 3038–3040 (2005).
   PubMedGoogle Scholar
• Tsiodras S, Zafiropoulou R, Giotakis J, Imbrios G, Antoniades A, Manesis EK. Deep sinus aspergillosis in a liver transplant recipient successfully treated with a combination of caspofungin and voriconazole. Transpl. Infect. Dis.6, 37–40 (2004).
   PubMedGoogle Scholar
• Lin SJ, Schranz J, Teutsch SM. Aspergillosis case–fatality rate: systematic review of the literature. Clin. Infect. Dis.32, 358–366 (2001).
   PubMed Web of Science ®Google Scholar
• Al-Rezqi A, Hawkes M, Doyle J, Richardson SE, Allen U. Invasive mold infections in iatrogenically immunocompromised children: an eight-yr review. Pediatr. Transplant13(5), 545–552 (2009).
   PubMedGoogle Scholar